Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 3Thoracic 2Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 2

Interventions

Carboplatin 1152Cisplatin 876Pemetrexed 834pembrolizumab 608Paclitaxel 598Docetaxel 535Gemcitabine 424Radiotherapy 377Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 295durvalumab 254Drug Therapy 233osimertinib 218atezolizumab 208Radiosurgery 190Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 124Magnetic Resonance Spectroscopy 121Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × glumetinib × Thoracic × Clear all
NCT06829459 2025-04-08

A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs

Shanghai JMT-Bio Inc.

Phase 3 Recruiting
350 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06452433 2024-06-11

Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting
91 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡